IV fosphenytoin in obese patients: Dosing strategies, safety, and efficacy

Neurology. Clinical Practice
Sarah L ClarkSara E Hocker

Abstract

Previous studies evaluated the disposition of IV phenytoin loading doses and found that obese patients had increased drug distribution into excess body weight, larger volumes of distribution, and longer half-lives when compared to their nonobese counterparts. We assess the safety and efficacy of fosphenytoin loading doses in patients with different body mass indices (BMIs). A retrospective chart review was conducted in 410 patients who received fosphenytoin. Patients were divided into 2 groups: BMI <30 (nonobese) and BMI ≥30 (obese). Patient demographics, fosphenytoin dose administered in mg/kg body weight, renal and liver function tests, fosphenytoin drug levels, and pre- and post-fosphenytoin administration vital signs were collected to assess for adverse events. Necessity of additional antiepileptic loading doses was used as a surrogate for clinical efficacy. The median dose of fosphenytoin administered was 19 mg/kg (interquartile range 15-20). The most frequently encountered adverse event was hypotension, which occurred in 39% of the cohort. Using a Bonferroni adjustment for multiple comparisons, there were no differences in adverse events between the 2 groups. The need for additional antiepileptic loading doses was not dif...Continue Reading

References

Dec 1, 1988·Clinical Pharmacology and Therapeutics·B A BoucherT C Fabian
Sep 1, 1988·Drug Intelligence & Clinical Pharmacy·G M de OcaJ D Robinson
May 1, 1986·Clinical Pharmacokinetics·D R Abernethy, D J Greenblatt
May 1, 1985·Archives of Neurology·D R Abernethy, D J Greenblatt
Mar 1, 1982·Clinical Pharmacokinetics·D R Abernethy, D J Greenblatt
Jun 1, 1996·Neurology·T R BrowneM A Eldon
Nov 15, 1996·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·L S FierroD A Benezra
Oct 1, 1996·Journal of Emergency Nursing : JEN : Official Publication of the Emergency Department Nurses Association·K Bradbury-Golas, L Carson
Oct 31, 1998·Journal of Child Neurology·L E Knapp, A R Kugler
Dec 20, 2002·Clinical Pharmacokinetics·James H FischerPatricia A Fischer
Mar 6, 2004·Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine·Stuart P SwadronMichael Orlinsky
Sep 9, 2008·Epilepsia·Jagaralapudi Murali K Murthy, Sudesh Prabhakar
Oct 30, 2008·Pharmacotherapy·Sandrina L von WinckelmannLudo Willems
Jan 14, 2010·Clinical Pharmacokinetics·Michael J HanleyDavid J Greenblatt
Aug 6, 2010·The American Journal of Emergency Medicine·Patrick Michael AaronsonThomas A Kunisaki
Apr 25, 2012·Neurocritical Care·Gretchen M BrophyUNKNOWN Neurocritical Care Society Status Epilepticus Guideline Writing Committee
May 9, 2012·Neurocritical Care·Aaron M CookUNKNOWN Neurocritical Care Pharmacy Study Group
Oct 26, 2012·Neurocritical Care·James J RivielloUNKNOWN Neurocritical Care Society Status Epilepticus Guideline Writing Committee
May 8, 2013·Journal of the Neurological Sciences·Aasef G Shaikh
Apr 17, 2014·BMJ : British Medical Journal·Heather Angus-Leppan
Sep 27, 2014·Critical Care Clinics·Fawaz Al-Mufti, Jan Claassen
Oct 17, 2014·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Adam BrancaccioGeorge Delgado
Oct 24, 2014·Annual Review of Pharmacology and Toxicology·Catherijne A J KnibbeMeindert Danhof
Jul 3, 2015·Journal of Medical Toxicology : Official Journal of the American College of Medical Toxicology·Lyudmila A GarbovskyJeanmarie Perrone
Aug 21, 2015·Expert Review of Neurotherapeutics·Monika PopławskaStanisław J Czuczwar
Sep 25, 2015·Therapeutic Drug Monitoring·Mindl M MessingerAngus Wilfong
Oct 2, 2015·Continuum : Lifelong Learning in Neurology·Sara E Hocker

❮ Previous
Next ❯

Citations

Sep 27, 2019·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Sherif Hanafy MahmoudS Nizam Ahmed

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.